Bristol-Myers
Executive Summary
Announces agreements with Nippon Kayaku, Takara Shuzo and the Institute of Microbial Chemistry to develop deoxyspergualin, a potential anticancer and immunosuppressive agent. Phase II trials with deoxyspergualin are underway at NCI and clinical trials for kidney transplantation and autoimmune disease are planned in Japan. Hoechst is conducting trials in Europe. Scientific papers on the drug were presented at the 12th International Congress of the Transplantation Society in Sydney, Australia.
Announces agreements with Nippon Kayaku, Takara Shuzo and the
Institute of Microbial Chemistry to develop deoxyspergualin, a
potential anticancer and immunosuppressive agent. Phase II
trials with deoxyspergualin are underway at NCI and clinical trials
for kidney transplantation and autoimmune disease are planned in
Japan. Hoechst is conducting trials in Europe. Scientific papers on
the drug were presented at the 12th International Congress of the
Transplantation Society in Sydney, Australia. |